BioNTech (BNTX) Stock Price Today—Real Time Charts and Quotes

Q: What's the stock price of BioNTech (BNTX) today?

BioNTech (BNTX) is currently trading at $102.06, with a 24h change of -0.04%. The 52-week trading range is $79.5–$124.

Q: What are the 52-week high and low prices for BioNTech (BNTX)?

BNTX has a 52-week high of $124 and a 52-week low of $79.5, with the current price at $102.06.

Q: What is the price-to-earnings (P/E) ratio of BioNTech (BNTX)? What does it indicate?

The current P/E ratio (TTM) of BNTX is -17.945909712145248, indicating how much investors pay for each dollar of earnings. A higher P/E ratio often reflects stronger growth expectations, while a lower P/E ratio may suggest a more attractive valuation or slower growth. Comparing it with the average P/E of the Biotechnology industry for a better context.

Q: What is the market cap of BioNTech (BNTX)?

BioNTech (BNTX) currently has a market cap of approximately $25.65B.

Q: What is the most recent quarterly earnings per share (EPS) for BioNTech (BNTX)?

BioNTech (BNTX)'s diluted earnings per share (Diluted EPS) is -4.622957025515838. EPS = Net Income / Total Diluted Shares, which is a key metric for measuring a company's profitability.

Q: Should you buy or sell BioNTech (BNTX) now?

As of now, BNTX is trading at $102.06, with a P/E ratio of -17.945909712145248 and a diluted EPS of -4.622957025515838. Your buy or sell decisions should be based on your investment goals and risk tolerance. We recommend making an overall judgment by considering BioNTech's financial reports, the outlook of the Biotechnology sector, and your own holdings. Investing involves risk—please make decisions prudently.

Q: What factors can affect the stock price of BioNTech (BNTX)?

Key factors include: company quarterly reports (revenue, EPS), competition and trends in the Biotechnology sector, macroeconomic environment (interest rate, inflation), market sentiment, as well as major events like product releases and mergers & acquisitions.

Q: How to buy BioNTech (BNTX) stock?

You can buy BioNTech (BNTX) through Gate. Sign up for a Gate account and complete identity verification, then go to the BioNTech trading page to make a purchase. Gate supports fractional share trading, so you can start investing without buying a whole share.

$102,06

-$0,05(-0,04%)

*Data last updated: 2026-04-28 23:28 (UTC+8)

As of 2026-04-28 23:28, BioNTech (BNTX) is priced at $102,06, with a total market cap of $25,65B, a P/E ratio of -17,94, and a dividend yield of 0,00%. Today, the stock price fluctuated between $100,69 and $102,25. The current price is 1,36% above the day's low and 0,18% below the day's high, with a trading volume of 516,83K. Over the past 52 weeks, BNTX has traded between $79,50 to $124,00, and the current price is -17,69% away from the 52-week high.

BNTX Key Stats

Yesterday's Close$102,06

Market Cap$25,65B

Volume516,83K

P/E Ratio-17,94

Dividend Yield (TTM)0,00%

Dividend Amount$2,11

Diluted EPS (TTM)4,63

Net Income (FY)-$1,09B

Revenue (FY)$2,75B

Earnings Date2026-05-05

EPS Estimate2,52

Revenue Estimate$210,15M

Shares Outstanding251,32M

Beta (1Y)1.593

Ex-Dividend Date2022-06-02

Dividend Payment Date2022-06-17

About BNTX

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

SectorHealthcare

IndustryBiotechnology

CEOUgur Sahin

HeadquartersMainz,None,DE

Official Websitehttps://www.biontech.de

Employees (FY)7,80K

Average Revenue (1Y)$353,09K

Net Income per Employee-$139,77K

BioNTech (BNTX) FAQ

What's the stock price of BioNTech (BNTX) today?

BioNTech (BNTX) is currently trading at $102,06, with a 24h change of -0,04%. The 52-week trading range is $79,50–$124,00.

What are the 52-week high and low prices for BioNTech (BNTX)?

What is the price-to-earnings (P/E) ratio of BioNTech (BNTX)? What does it indicate?

What is the market cap of BioNTech (BNTX)?

What is the most recent quarterly earnings per share (EPS) for BioNTech (BNTX)?

Should you buy or sell BioNTech (BNTX) now?

What factors can affect the stock price of BioNTech (BNTX)?

How to buy BioNTech (BNTX) stock?

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.